The Signaling Pathway of the ADP Receptor P2Y in the Immune System: Recent Discoveries and New Challenges

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 13

PMID 37047682

Authors

Philomena Entsie

Ying Kang

Emmanuel Boadi Amoafo

Torsten Schoneberg

Elisabetta Liverani

Affiliations

Soon will be listed here.

Abstract

P2Y is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease patients. However, receptor studies have shown that P2Y is functionally expressed not only in platelets and the microglia but also in other cells of the immune system, such as in monocytes, dendritic cells, and T lymphocytes. As a result, studies were carried out investigating whether therapies targeting P2Y could also ameliorate inflammatory conditions, such as sepsis, rheumatoid arthritis, neuroinflammation, cancer, COVID-19, atherosclerosis, and diabetes-associated inflammation in animal models and human subjects. This review reports what is known about the expression of P2Y in the cells of the immune system and the effect of P2Y activation and/or inhibition in inflammatory conditions. Lastly, we will discuss the major problems and challenges in studying this receptor and provide insights on how they can be overcome.

Citing Articles

The role of the P2X7 receptor in inactivated SARS-CoV-2-induced lung injury.

Carvalho-Barbosa N, Cristina-Rodrigues F, Temerozo J, Souza T, Gouvea A, Canetti C Purinergic Signal. 2024; .

PMID: 39607622 DOI: 10.1007/s11302-024-10062-7.

Impact of P2Y12 inhibitors on clinical outcomes in sepsis-3 patients receiving aspirin: a propensity score matched analysis.

Jiang S, Xu J, Ke C, Huang P BMC Infect Dis. 2024; 24(1):575.

PMID: 38862910 PMC: 11167871. DOI: 10.1186/s12879-024-09421-x.

Platelets, inflammation, and purinergic receptors in chronic kidney disease.

Corken A, Ong V, Kore R, Ghanta S, Karaduta O, Pathak R Kidney Int. 2024; 106(3):392-399.

PMID: 38821448 PMC: 11343655. DOI: 10.1016/j.kint.2024.03.033.

The Multifaceted Effects of Non-Steroidal and Non-Opioid Anti-Inflammatory and Analgesic Drugs on Platelets: Current Knowledge, Limitations, and Future Perspectives.

Tsoupras A, Gkika D, Siadimas I, Christodoulopoulos I, Efthymiopoulos P, Kyzas G Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794197 PMC: 11124379. DOI: 10.3390/ph17050627.

A role for platelets in metabolic reprogramming of tumor-associated macrophages.

Kang Y, Amoafo E, Entsie P, Beatty G, Liverani E Front Physiol. 2023; 14:1250982.

PMID: 37693009 PMC: 10484008. DOI: 10.3389/fphys.2023.1250982.

References

Ganbaatar B, Fukuda D, Salim H, Nishimoto S, Tanaka K, Higashikuni Y . Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis. 2018; 275:124-132. DOI: 10.1016/j.atherosclerosis.2018.05.053. View

Liverani E, Rico M, Garcia A, Kilpatrick L, Kunapuli S . Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther. 2012; 344(1):231-43. PMC: 3533408. DOI: 10.1124/jpet.112.195883. View

Yu X, Yu C, He W . Emerging trends and hot spots of NLRP3 inflammasome in neurological diseases: A bibliometric analysis. Front Pharmacol. 2022; 13:952211. PMC: 9490172. DOI: 10.3389/fphar.2022.952211. View

Remijn J, Wu Y, Jeninga E, IJsseldijk M, Willigen G, de Groot P . Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol. 2002; 22(4):686-91. DOI: 10.1161/01.atv.0000012805.49079.23. View

Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O . P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab. 2004; 90(2):920-7. DOI: 10.1210/jc.2004-0137. View

Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S . Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia. 2007; 55(6):604-16. DOI: 10.1002/glia.20489. View

Schreuder M, Badal R, Boersma E, Kavousi M, Roos-Hesselink J, Versmissen J . Efficacy and Safety of High Potent P2Y Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020; 9(4):e014457. PMC: 7070195. DOI: 10.1161/JAHA.119.014457. View

Kaufmann C, Lyon A, Wojta J, Huber K . Is P2Y12 inhibitor therapy associated with an increased risk of cancer?. Eur Heart J Cardiovasc Pharmacother. 2019; 5(2):100-104. DOI: 10.1093/ehjcvp/pvz003. View

Turner N, Moake J, McIntire L . Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001; 98(12):3340-5. DOI: 10.1182/blood.v98.12.3340. View

10.

Morel O, Ghannudi S, Hess S, Reydel A, Crimizade U, Jesel L . The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost. 2012; 108(2):338-48. DOI: 10.1160/TH11-12-0876. View

11.

Scherer H, Haupl T, Burmester G . The etiology of rheumatoid arthritis. J Autoimmun. 2020; 110:102400. DOI: 10.1016/j.jaut.2019.102400. View

12.

Bhavaraju K, Mayanglambam A, Rao A, Kunapuli S . P2Y(12) antagonists as antiplatelet agents - Recent developments. Curr Opin Drug Discov Devel. 2010; 13(4):497-506. View

13.

Liverani E, Rico M, Tsygankov A, Kilpatrick L, Kunapuli S . P2Y12 Receptor Modulates Sepsis-Induced Inflammation. Arterioscler Thromb Vasc Biol. 2016; 36(5):961-71. PMC: 4850113. DOI: 10.1161/ATVBAHA.116.307401. View

14.

Ballerini P, Dovizio M, Bruno A, Tacconelli S, Patrignani P . P2Y Receptors in Tumorigenesis and Metastasis. Front Pharmacol. 2018; 9:66. PMC: 5801576. DOI: 10.3389/fphar.2018.00066. View

15.

Gurbel P, Bliden K, Butler K, Antonino M, Wei C, Teng R . Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010; 121(10):1188-99. DOI: 10.1161/CIRCULATIONAHA.109.919456. View

16.

Boilard E, Nigrovic P, Larabee K, Watts G, Coblyn J, Weinblatt M . Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010; 327(5965):580-3. PMC: 2927861. DOI: 10.1126/science.1181928. View

17.

Foster C, Prosser D, Agans J, Zhai Y, Smith M, Lachowicz J . Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001; 107(12):1591-8. PMC: 200194. DOI: 10.1172/JCI12242. View

18.

Hardy A, Conley P, Luo J, Benovic J, Poole A, Mundell S . P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005; 105(9):3552-60. DOI: 10.1182/blood-2004-07-2893. View

19.

Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I . P2Y Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci. 2020; 21(4). PMC: 7073040. DOI: 10.3390/ijms21041391. View

20.

Siegel P, Sander L, Fricke A, Stamm J, Wang X, Sharma P . PY receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. Sci Rep. 2021; 11(1):17459. PMC: 8408182. DOI: 10.1038/s41598-021-95710-3. View